We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Mogrify and Astellas Announce Collaboration To Conduct Research on In Vivo Regenerative Medicine Approaches To Address Sensorineural Hearing Loss


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Mogrify and Astellas Announce Collaboration To Conduct Research on In Vivo Regenerative Medicine Approaches To Address Sensorineural Hearing Loss"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) have announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.


Utilizing Mogrify’s proprietary direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair cells. As part of the collaboration, Astellas Gene Therapies, a division of Astellas, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus (AAV) based genetic medicine and translational capabilities to complete experiments in pre-clinical models. Mogrify will exploit its bioinformatic platform, screening and validation process to characterize potential therapeutic factors.


An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2. This degree of hearing loss significantly reduces quality of life and, with no drug treatments currently available, represents a large unmet need.


Dr. Louise Modis, CSO, Mogrify, said:Mogrify’s human regulatory network-centric approach is well placed to identify superior factor combinations, therefore increasing the efficiency of direct conversion toward the target cell type in the ear. Combined with Astellas’ capabilities for gene therapy and research of sensorineural, this provides a clear path for the development of a novel in vivo reprogramming therapy for sensorineural hearing loss.”


Dr. Mathew Pletcher, Senior VP, Division Head of Gene Therapy Research & Technical Operations, Astellas, said: “In this collaboration, we will look to combine the unique delivery attributes of AAV-based gene therapy, with our deep translational capabilities in otology developed through our “Targeted Therapeutics for Auditory Regeneration”, and “Direct Reprogramming (Transdifferentiation)” initiatives. Through this collaboration, we will seek to address a significant unmet need in sensorineural hearing loss.”


1. Hearing Loss Collaborators. Hearing loss prevalence and years lived with disability, 1990-2019: findings from the Global Burden of Disease Study 2019. Lancet. 2021 Mar 13;397(10278):996-1009.


2. Goman AM, Lin FR. Prevalence of Hearing Loss by Severity in the United States. Am J Public Health. (2016);106(10):1820-1822.

  

Advertisement